LFCR Financials

Income Statement
MetricQ1 2027Q4 2026Q2 2026Q1 2025Q3 2025
Revenue
34.2M
+47.3%
23.2M
-25.4%
31.1M
-14.6%
36.4M
+3.7%
35.2M
Cost of Revenue
22.1M
+17.9%
18.7M
-19.7%
23.3M
+3.8%
22.5M
-11.2%
25.3M
Gross Profit
12.1M
+170.6%
4.5M
-42.7%
7.8M
-44.3%
14.0M
+42.0%
9.8M
Operating Expenses
9.5M
+4.1%
9.1M
-15.9%
10.9M
+26.8%
8.6M
-28.8%
12.0M
R&D
1.5M
+26.3%
1.2M
-38.0%
2.0M
-6.7%
2.1M
+2.8%
2.0M
SG&A
8.0M
+0.7%
7.9M
-11.0%
8.9M
-0.9%
9.0M
-11.0%
10.1M
Operating Income
2.6M
+154.9%
-4672000
-52.3%
-3067000
-156.6%
5.4M
+348.8%
-2178000
EBITDA
2.6M
+208.7%
-2362000
-117.5%
-1086000
-137.5%
2.9M
+1435.9%
-217000
Net Income
-6156000
+58.9%
-14980000
-49.9%
-9991000
-771.1%
-1147000
+92.2%
-14769000
EPS (Basic)
$-0.19
+55.8%
$-0.43
-48.3%
$-0.29
-383.3%
$-0.06
+87.2%
$-0.47
EPS (Diluted)
$-0.19
+55.8%
$-0.43
-48.3%
$-0.29
-383.3%
$-0.06
+87.2%
$-0.47
Shares (Diluted)
37.6M
+0.3%
37.5M
+0.2%
37.4M
+1.1%
37.0M
-0.0%
37.0M
Lifecore Biomedical (LFCR) โ€” Financials